Grifols SA business relationships

Companies named in Grifols SA’s 20-F filed 2026-04-17, and public companies whose annual reports name Grifols SA. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 6.6 / 10
AI naming: 100 / 100
Agent readiness: 0 / 100
AI adoption: 0 / 100

Named in Grifols SA’s annual report 5

SIEMENSSupplier7.7
“...ment with Ortho under which we continue as exclusive supplier of antigens to Ortho, while retaining the right to supply antigens to third parties (including Abbott Laboratories, Siemens and OraSure Technologies) and to develop products independently, subject to customary intellectual property terms.” SEC filing
ABBOTT LABORATORIES (ABT)Supplier6.7
“...ment with Ortho under which we continue as exclusive supplier of antigens to Ortho, while retaining the right to supply antigens to third parties (including Abbott Laboratories, Siemens and OraSure Technologies) and to develop products independently, subject to customary intellectual property terms.” SEC filing
ORASURE TECHNOLOGIES INC (OSUR)Supplier6.6
“...ment with Ortho under which we continue as exclusive supplier of antigens to Ortho, while retaining the right to supply antigens to third parties (including Abbott Laboratories, Siemens and OraSure Technologies) and to develop products independently, subject to customary intellectual property terms.” SEC filing
Biotest AGDistributor4.6
“At 31 December 2025, "other current financial liabilities" include mainly distributor commission liabilities of Euros 14 million corresponding to Biotest, AG (Euros 23 million at 31 December 2024).” SEC filing
Biotest AGPartner4.6
“Biotest AG is the parent company of a consolidated group of companies, which includes a joint venture investment corresponding to a 49 % interest held by Biotest Pharma GmbH in BioDarou P.J.S.” SEC filing

Companies whose annual reports name Grifols SA 5

QuidelOrtho Corp (QDEL)names it as customer6.1
“During fiscal year ended 2025, the revenue associated with the use of this patented intellectual property was less than 1% of our total revenues and the expense associated with the antigens supplied to us by Grifols was less than 2% of our cost of goods sold.” SEC filing
QuidelOrtho Corp (QDEL)names it as partner6.1
“The Company has the Joint Business between Ortho and Grifols, under which Ortho and Grifols agreed to pursue a collaboration relating to Ortho's Hepatitis and HIV diagnostics business.” SEC filing
RIGEL PHARMACEUTICALS INC (RIGL)names it as licensor5.5
“We have a commercialization license agreement with Grifols for exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop, fostamatinib in their territory.” SEC filing
RIGEL PHARMACEUTICALS INC (RIGL)names it as partner5.5
“As of December 31, 2025, 89 % of our accounts receivable are outstanding invoices to our customers related to product sales in the US, and the remaining 11 % are outstanding invoices from our collaboration partners, mainly Grifols.” SEC filing
ADMA BIOLOGICS, INC. (ADMA)names it as supplier4.9
“In December 2018, our former contract manufacturer assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 2019.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.